Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02108457 · ClinicalTrials.gov registry record

[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers

A clinical trial of Gynecologic Cancer, sponsored by Abramson Cancer Center at Penn Medicine.

Completed
Registry status
15
Enrollment target
1
Study location

NCT02108457: Completed study of Gynecologic Cancer, sponsored by Abramson Cancer Center at Penn Medicine.

NCT02108457 is a study of Gynecologic Cancer that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 15 participants, below the 764-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02108457, a study of Gynecologic Cancer, has completed, sponsored by Abramson Cancer Center at Penn Medicine.

COMPLETED
Registry status
15 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the effect of specific bone marrow maps developed with18F-FLT PET/CT imaging on the ability to spare proliferating bone marrow using proton beam radiotherapy compared to IMRT. Participants will be 18 years of age or old with a history of gynecologic cancer. Subjects will undergo 3 FLT-PET scans (one before treatment, one during the course of RT, and one 2-5 weeks after initiation of RT). Scans will take place in the Department of Radiation Oncology.

Conditions Studied

Gynecologic Cancer

Interventions

  • RADIATION [18F]Fluorothymidine (FLT) PET/CT Imaging

Study Locations (1)

Pennsylvania

  • Abramson Cancer Center of the University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2014-02
Est. Completion 2016-12-21
Abramson Cancer Center at Penn Medicine

402 total trials

What the finished NCT02108457 record still lists

NCT02108457 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 764-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Gynecologic Cancer appearing as the primary indexed condition, and to 1 intervention - of which [18F]Fluorothymidine (FLT) PET/CT Imaging is the first listed.

NCT02108457 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02108457 about?

NCT02108457 is a clinical study titled "[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers". The purpose of this study is to determine the effect of specific bone marrow maps developed with18F-FLT PET/CT imaging on the ability to spare proliferating bone marrow using proton beam radiotherapy compared to IMRT. Participants will be 18 years of age or old with a history of gynecologic cancer. ...

What is the current status of trial NCT02108457?

This trial is currently completed. The enrollment target is 15 participants. The study started on 2014-02. Estimated completion is 2016-12-21.

What conditions does trial NCT02108457 study?

This clinical trial studies the following conditions: Gynecologic Cancer.

What interventions are being tested in trial NCT02108457?

The interventions under investigation include: [18F]Fluorothymidine (FLT) PET/CT Imaging (RADIATION).

Who is sponsoring clinical trial NCT02108457?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02108457 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gynecologic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02108457's enrollment target sits among peer trials

15 53rd of 55 higher than 3 of 55 other Gynecologic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gynecologic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02108457, the US trial registry maintained by the National Library of Medicine. NCT02108457 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.